Resproly is a respiratory system inhalation therapy and device developer.
Resproly is a research and development, production and sales of formula and equipment for respiratory inhalation. An integrated enterprise that focuses on multiple clinically demanding treatment areas such as Asthma, Chronic Obstructive Pulmonary Disease (COPD), Diabetes, and Parkinson's Disease.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 29, 2019 | Series A | ¥50M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Shenzhen Yanghe Biopharmaceutical Industry Investment | — | Series A |
Huaige Capital | — | Series A |